Related Experiment Video
Updated: Mar 30, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck
Jean-Pascal Machiels1, Sandra Schmitz1
1Departments of Medical Oncology and Head and Neck Surgery, King Albert II Institute, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (IREC), Université catholique de Louvain, 10 avenue Hippocrate, Brussels 1200, Belgium.
Abstract:
Overexpression of epidermal growth factor receptor (EGFR) is linked with poor prognosis in squamous cell carcinoma of the head and neck (SCCHN). Cetuximab binds specifically to EGFR with high affinity; combined with radiotherapy, it improves locoregional control and survival over radiotherapy alone. Adding cetuximab to platinum-based chemotherapy and 5-fluorouracil improves overall survival in incurable disease. Only a minority of patients benefit from anti-EGFR monoclonal antibodies. A better understanding of the molecular mechanisms involved in treatment resistance and identification of predictive biomarkers are crucial. Potentially more potent anti-EGFR compounds are currently under investigation with the aim of improving treatment efficacy.
Related Concept Videos
Mitogens and the Cell Cycle
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Inhibition of CDK Activity
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

